Form 8-K - Current report:
SEC Accession No. 0001641172-25-024088
Filing Date
2025-08-14
Accepted
2025-08-14 16:37:09
Documents
14
Period of Report
2025-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 42419
2 EX-99.1 ex99-1.htm EX-99.1 14122
3 GRAPHIC ex99-1_001.jpg GRAPHIC 8955
  Complete submission text file 0001641172-25-024088.txt   235195

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE eltp-20250814.xsd EX-101.SCH 3023
5 XBRL LABEL FILE eltp-20250814_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE eltp-20250814_pre.xml EX-101.PRE 22364
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3467
Mailing Address 165 LUDLOW AVENUE NORTHVALE NJ 07647
Business Address 165 LUDLOW AVENUE NORTHVALE NJ 07647 2017502646
ELITE PHARMACEUTICALS INC /NV/ (Filer) CIK: 0001053369 (see all company filings)

EIN.: 223542636 | State of Incorp.: NJ | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-15697 | Film No.: 251220171
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)